MedPath

Ultrasound Index Fat Fraction

Not Applicable
Not yet recruiting
Conditions
Steatosis of Liver
Interventions
Device: Echographic scan
Registration Number
NCT06373796
Lead Sponsor
SuperSonic Imagine
Brief Summary

The objective is to compare the ultrasound index fat fraction (FAT PLUS), derived from several ultrasound biomarkers, with the gold-standard imaging exam for liver fat content evaluation (MRI-PDFF) in patients to quantify the hepatic steatosis.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Subject is ≥ 18 years old.
  • Subject is able to understand and sign the Informed Consent Form.
  • Subject is able to stand and walk independently.
  • Subject must have at least one or more routine ultrasound imaging procedures of the abdomen, at one of the participating study sites.
  • Subject must have at least one routine liver MRI with PDFF score performed within 30 days before or after the ultrasound examination
  • Subject is affiliated to National Social Insurance or a Health Insurance Regimen
Exclusion Criteria
  • Subject is unable or unwilling to adhere to Study procedures
  • Subject is unable to understand the Informed Consent
  • Subject is unable to express its consent
  • Subject is under legal protection
  • Subject is deprived of liberty by judicial or administrative decision
  • Subject undergoes psychiatric treatment under constraint
  • Subject is pregnant or breastfeeding
  • Subject has latex allergy
  • Subject has an open wound, cut, and/or a rash which would preclude an ultrasound imaging procedure

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
FAT PLUSEchographic scan-
Primary Outcome Measures
NameTimeMethod
FAT PLUS3 months

The objective is to compare the ultrasound index fat fraction (FAT PLUS), derived from several ultrasound biomarkers, with the gold-standard imaging exam for liver fat content evaluation (MRI-PDFF) in patients to quantify the hepatic steatosis.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath